Legacy ramps up preparations for new Russian track and trace sterilisation regulations
![](/46/pdcnewsitem/07/89/84/Legacy-ramps-up-preparations-for-new-Russian-track-and-trace-sterilisation-regulations.jpg)
Company to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding.
Legacy Pharmaceuticals, a global contract manufacturer of sterile/aseptic pharmaceutical products in ampoules and vials, has announced that preparations to meet the new Russian track and trace regulation, Federal Law No. 425-FZ, are well advanced.
Due to be introduced in January 2020, the regulation sets a new bar for serialization, compliance reporting and data management.
“The Russian regulations are even more stringent that the newly implemented serialization systems Legacy recently installed to meet the EU Falsified Medicines Directive in 2018. The addition of cryptographic coding in particular, which adds another layer to security, is a significant technical challenge,” says Legacy CEO Mike Danzi.
“However, Russia has always been one of our key markets and we are committed to ensure our longstanding customers can continue to rely on our products. We are preparing to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding. New Bosch serialization and aggregation equipment has already been installed and certified on three packaging lines. Complex labelling containing a wide range of readable/variable data and DMC-codes is now possible.
Two types of tamper-evident labels are available for different packaging materials including cartons, styrofoam boxes, and bottles. Legacy is committed to the Russia market, and to leading the way to comply with the new serialization requirements.”
![Legacy Pharmaceuticals Switzerland GmbH](https://www.cphi-online.com/th278367-comp278367.png)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance